Table 2.
Results from assessing the second prerequisite, existence of clinical predictors for the log(SD) of HbA1c values after treatment
| Predictor | Number of missing arms for the predictor | Slope of adjusted regression line in: | Slope difference (verum−placebo) (95% CI) | |
|---|---|---|---|---|
| Verum arms (95% CI) | Placebo arms (95% CI) | |||
| Mean age at baseline (in years) | 18 | −0.001 (−0.012, 0.010) | 0.002 (−0.009, 0.014) | −0.003 (−0.008, 0.003) |
| Proportion of male participants at baseline (in %) | 25 | −0.001 (−0.005, 0.002) | 0.001 (−0.003, 0.005) | −0.002 (−0.005, 0.0003) |
| Mean BMI at baseline (in kg/m2) | 16 | 0.014 (−0.004, 0.0316) | 0.010 (−0.009, 0.028) | 0.004 (−0.009, 0.016) |
| Mean disease duration at baseline (in years) | 92 | 0.007 (−0.009, 0.023) | −0.004 (−0.021, 0.012) | 0.011 (0.002, 0.021) |
| Mean HbA1c at baseline (in mmol/mol) | 0 | 0.006 (−0.001, 0.013) | 0.003 (−0.005, 0.010) | 0.003 (−0.001, 0.007) |
| Mean HbA1c at baseline (in %) | 0 | 0.065 (−0.010, 0.140) | 0.031 (−0.052, 0.114) | 0.034 (−0.008, 0.076) |
| Duration of treatment (in weeks) | 0 | 0.001 (−0.0005, 0.002) | 0.001 (−0.0005, 0.002) | 0.00004 (−0.00038, 0.00030) |
| Year | 0 | −0.008 (−0.016, 0.0005) | −0.006 (−0.014, 0.003) | −0.002 (−0.008, 0.003) |
Each line reports on a separate meta-regression model for each individual predictor. The models are identical to the models for the first prerequisite, however, they were extended by an additional interaction term of the respective predictor with treatment. Given are the slopes of regression lines for the respective predictor in the placebo and the verum arms, as well as their difference, which actually measures the interaction between treatment and predictor